BioCentury | Mar 20, 2020
Finance

Strong investor demand for InnoCare on HK exchange despite pandemic concerns

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the...
BioCentury | Feb 1, 2020
Company News

Any chance left for safer opioids?

The future is looking bleak for new opioids. Between a pair of advisory committee meetings this month that delivered two blows to abuse-deterrent candidates, and the discontinuation of at least half of the newest market...
BioCentury | Jan 11, 2019
Financial News

InnoCare raises $160M to advance Btk inhibitor

InnoCare Pharma Ltd. (Beijing, China) said on Jan. 4 that it raised $160 million in a venture round led by Loyal Valley Capital with participation from 3H Health Investment, Epiphron Capital Fund II and existing...
BioCentury | Jan 4, 2019
Financial News

InnoCare raises $160M to advance Btk inhibitor

InnoCare Pharma Ltd. (Beijing, China) said Friday that it raised $160 million in a venture round led by Loyal Valley Capital with participation from 3H Health Investment, Epiphron Capital Fund II and existing investors Vivo...
BioCentury | Feb 16, 2018
Finance

Global access

Vivo Capital could help InnoCare Pharma Ltd. seek global development partners as the Chinese cancer and autoimmune company evaluates its first four candidates in the clinic. Vivo, a new investor, led an untranched $55 million...
BioCentury | Sep 29, 2017
Clinical News

Genocea discontinues HSV-2 candidate GEN-003

...expects an annual savings of $6.5 million. The T cell vaccine consists of the infected cell polypeptide 4 (ICP4...
...Product: GEN-003 Business: Infectious Molecular target: Infected cell polypeptide 4 (ICP4) Description: T cell vaccine consisting of the ICP4...
...virus type 2 (HSV-2) infection Endpoint: NA Status: Development discontinued Milestone: NA Chris Lieu GEN-003 GEN-009 Genocea Biosciences Inc. Infected cell polypeptide 4 (ICP4...
BioCentury | Sep 8, 2017
Product Development

Maximizing neoantigens

In conjunction with raising $55 million in a series B round on Friday, Replimune Group Inc. unveiled details of its Immulytic oncolytic virus platform, including next-generation constructs that underpin the company’s strategy for creating multimodal...
BioCentury | Aug 22, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest mesenchymal stem cells (MSCs) loaded with oncolytic herpes simplex virus (HSV) could help treat the dispersed brain metastases of melanoma. In a human melanoma lymph node metastasis...
BioCentury | Oct 10, 2016
Clinical News

GEN-003: Phase IIb data

...GEN-003 Business: Infectious Molecular target: Infected cell polypeptide 4 (ICP4) Description: T cell vaccine consisting of the infected cell polypeptide 4 (ICP4...
BioCentury | Apr 4, 2016
Clinical News

GEN-003: Additional Phase II data

...GEN-003 Business: Infectious Molecular target: Infected cell polypeptide 4 (ICP4) Description: T cell vaccine consisting of the infected cell polypeptide 4 (ICP4...
Items per page:
1 - 10 of 51